Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low
Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior TherapyLate-Breaking Abstract Featured as an Oral Presentation during a Plenary Session at the Annual Global Meeting o...
Source: pharmiweb.com